PGFC
MCRB icon

Peapack-Gladstone Financial Corp’s Seres Therapeutics MCRB Stock Holding History

Peapack-Gladstone Financial Corp’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-650
Closed -$9K – 694
2025
Q1 		$9K Buy
+650
New +$10.2K ﹤0.01% 671

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Peapack-Gladstone Financial Corp's MCRB Position: Q2 2025 in Review

Peapack-Gladstone Financial Corp sold out of Seres Therapeutics (MCRB) in Q2 2025, closing a stake of 650 shares — an estimated $9K sold.

Peapack-Gladstone Financial Corp first reported a position in MCRB in Q1 2025 and held it in 1 quarter. The position peaked at $9K in Q1 2025. 33 funds tracked by Wall St. Rank hold MCRB as of Q2 2025.

  • Peapack-Gladstone Financial Corp reported no remaining Seres Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Peapack-Gladstone Financial Corp sold 650 Seres Therapeutics shares in Q2 2025, an estimated $9K.
  • Peapack-Gladstone Financial Corp first reported a position in Seres Therapeutics in Q1 2025 and held it in 1 quarter.
  • Peapack-Gladstone Financial Corp's Seres Therapeutics position peaked at $9K in Q1 2025.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2025.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q2 2025, filed 14 Aug 2025.